Skip to main content

Table 3 Characteristics of patients diagnosed with CD, Germany, 2000–2018

From: Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 – 2018

Sexa

Female

n = 52/81

(64.2%)

Male

n = 28/81

(34.6%)

All

n = 81

(100.0%)

Age in years at the time of testing

 Mean (SD)

43.3 years (SD = 3.8)

46.1 years (SD = 6.9)

44.0 years (SD = 3.4)

  ≤ 14

0

1 (3.6%)

1 (1.2%)

 15–49

35 (67.3%)

16 (57.1%)

51 (63.0%)

  ≥ 50

17 (32.7%)

11 (39.3%)

28 (34.6%)

 NA

0

0

1 (1.2%)

Nationality

Available on n = 26/52 (50.0%)

Available on n = 9/28 (32.1%)

Available on n = 35/81 (43.2%)

 Bolivia

13 (50.0%)

7 (77.8%)

20 (57.1%)

 Germany

0

2 (22.2%)

2 (5.7%)

 Brazil

5 (19.2%)

0

5 (14.3%)

 Paraguay

2 (7.7%)

0

2 (5.7%)

 Argentina

3 (11.5%)

0

3 (8.6%)

 Peru

2 (7.7%)

0

2 (5.7%)

 South America

1 (3.8%)

0

1 (2.9%)

Reason for testing

Available on n = 33/52 (63.5%)

Available on n = 12/28 (42.9%)

Available on n = 45/81 (55.6%)

 Known CD

17 (51.5%)

7 (58.3%)

24 (53.3%)

 Endemic national

7 (21.2%)

2 (16.7%)

9 (20.0%)

 Other

9 (27.3%)

3 (25.0%)

12 (26.7%)

Symptoms

Available on n = 23/52 (44.2%)

Available on n = 9/28 (32.1%)

Available on n = 32/81 (39.5%)

 Fatigue

0

2 (22.2%)

2 (6.3%)

 Gastrointestinal

9 (39.1%)

2 (22.2%)

11 (34.4%)

 Cardiac

3 (13.0%)

0

3 (9.4%)

 Other

1 (4.3%)

2 (22.2%)

3 (9.4%)

 No symptoms

10 (43.5%)

3 (33.3%)

13 (40.6%)

Initial diagnosis of CD

Available on n = 30/52 (57.7%)

Available on n = 13/28 (46.4%)

Available on n = 43/81 (53.1%)

 Yes

10 (33.3%)

5 (38.5%)

15 (34.9%)

 No

20 (66.7%)

8 (61.5%)

28 (65.1%)

Echocardiography

Available on n = 18/52 (34.6%)

Available on n = 5/28 (17.9%)

Available on n = 23/81 (28.4%)

 Normal

16 (88.9%)

3 (60.0%)

19 (82.6%)

 Abnormal

0

1 (20.0%)

1 (4.3%)

 Not performed

2 (11.1%)

1 (20.0%)

3 (13.0%)

Electrocardiography

Available on n = 18/52 (34.6%)

Available on n = 9/28 (32.1%)

Available on n = 27/81 (33.3%)

 Normal

16 (88.9%)

6 (66.7%)

22 (81.5%)

 Abnormal

2 (11.1%)

2 (22.2%)

4 (14.8%)

 Not performed

0

1 (11.1%)

1 (3.7%)

Etiologic treatment

Available on n = 22/52

(42.3%)

Available on n = 7/28

(25.0%)

Available on n = 29/81

(35.8%)

 Benznidazole

8 (36.4%)

3 (42.9%)

11 (37.9%)

 Nifurtimox

2 (9.1%)

0

2 (6.9%)

 No treatment

12 (54.5%)

4 (57.1%)

16 (55.2%)

Treatment course

Available on n = 8/10 (80.0%)

Available on n = 1/3 treatments

(33.3%)

Available on n = 9/13 treatments (69.2%)

 Completed treatment

5 (62.5%)

0

5 (55.6%)

 Stopped treatment

3 (37.5%)

1 (100%)

4 (44.4%)

Side effects

Available on n = 3/10 treatments

(30.0%)

Available on n = 1/3 treatments

(33.3%)

Available on n = 4/13 treatments

(30.8%)

 Yes

3 (100%)

1 (100%)

4 (100%)

 No

0

0

0

Reason for no treatment

Available on n = 11/12 (91.7%)

Available on n = 4/4

(100%)

Available on n = 15/16 (93.8%)

 Recommendations-based reason

5 (45.5%)

2 (50.0%)

7 (46.7%)

 Non-recommendations-based reason

6 (54.5%)

2 (50.0%)

8 (53.3%)

Follow-up

Available on n = 13/52 (25.0%)

Available on n = 4/28 (14.3%)

Available on n = 17/81 (21.0%)

 >  12 months

7 (53.8%)

3 (75.0%)

10 (58.8%)

 ≤ 12 months

4 (30.8%)

1 (25.0%)

5 (29.4%)

 No follow-up

2 (15.4%)

0

2 (11.8%)

  1. ain one CD case none of the data was available; CD Chagas disease, NA Not available, SD Standard deviation